Molecular insights into doxorubicin adsorption on graphene oxide: a combined theoretical and experimental study
1
item.page.dc.date.issued
2026-04-29
item.page.dc.type
item.page.dc.identifier.eissn
20545703
item.page.dc.identifier.doi
item.page.dc.identifier.scopus
2-s2.0-105045304445
item.page.oaire.citation.title
Royal Society Open Science
item.page.oaire.citation.volume
13
item.page.oaire.citation.issue
4
item.page.dc.rights.holder
SCOPUS
item.page.dc.identifier.citation
Royal Society Open Science Vol.13 No.4 (2026)
punsarn.item.page.citation
Katewongsa K.P., Sumetpipat K., Wongpan A., Tuncharoen R., Nuchpun S., Luksirikul P., Baowan D. Molecular insights into doxorubicin adsorption on graphene oxide: a combined theoretical and experimental study. Royal Society Open Science Vol.13 No.4 (2026). doi:10.1098/rsos.251785 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/118213
item.page.dc.title
Molecular insights into doxorubicin adsorption on graphene oxide: a combined theoretical and experimental study
item.page.dc.contributor.author
item.page.oairecerif.author.affiliation
item.page.dc.contributor.correspondence
item.page.dc.contributor.other
item.page.dc.description.abstract
Abstract – This study integrates mathematical modelling and experimental validation to investigate the fundamental interactions between the chemotherapeutic agent doxorubicin (DOX) and graphene oxide (GO), aiming to advance targeted drug delivery. Our theoretical approach, using the Lennard–Jones potential and the unified non-dominated sorting genetic algorithm III, successfully predicts the energetic landscape and optimal binding configurations of the DOX–GO system. These computational results are directly supported by our experimental findings on drug-loading capacity. We observe that a higher degree of GO oxidation leads to weaker interaction energy, a conclusion consistent with both our theoretical predictions and empirical data. This comprehensive methodology provides a molecular-level understanding of DOX–GO interactions, enabling the rational design of more efficient and therapeutically effective GO-based drug delivery platforms.
